Oberlies et al (1995) looked into the capacity of acetogenins to block, or hinder, the cell growth of growth cells. They tested this on numerous cell key ins vitro; cancerous cells from computer mice and also humans in addition to non-cancerous cells from the digestive system of rats. Results showed that the extra acetogenins were added to the malignant cells, a lot more the cell development was blocked. In addition, the non-cancerous healthy cells were not impacted by the acetogenins as well as the cell development was not obstructed. These searchings for could suggest that acetogenins can precisely obstruct the cell development of lump cells, while the healthy and balanced cells stay untouched with very little toxicity by this substance.
In breast cancer cells, the cancer cells gene ‘epidermal development aspect receptor’ (EGFR) is frequently overexpressed. For that reason, this cancer gene is a possible target for breast cancer therapy. A study by Dai et alia (2011) made use of a Soursop and the extract inhibited or blocked the expression of the EGFR genetics and this caused an inhibition of 32% of the development of breast cancer cells. The non-cancerous breast cells were not impacted by the fruit extract.
In 1997 Oberlies et alia investigated the capability of the acetogenins to obstruct the cell growth of particular lump cells, adriamycin resistant human mammary adenocarcinoma cells. These breast tumor cells are immune to therapy with adriamycin, vincristine as well as vinblastine. All 3 are anti-tumor drugs. Because these lump cells could not be treated with the medications, the lump is called multidrug resistant (MDR). The study team used different acetogenins derived from the Soursop. The ones with a specific framework (a stereochemistry of threo-trans-threo-trans-erythro) were one of the most powerful acetogenin and had 250 times the strength of adriamycin. This indicates that acetogenins could have a chemotherapeutical potential, also against MDR lumps.